ly 353381 has been researched along with tamoxifen in 24 studies
| Studies (ly 353381) | Trials (ly 353381) | Recent Studies (post-2010) (ly 353381) | Studies (tamoxifen) | Trials (tamoxifen) | Recent Studies (post-2010) (tamoxifen) |
|---|---|---|---|---|---|
| 70 | 12 | 15 | 20,630 | 2,227 | 6,256 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (75.00) | 29.6817 |
| 2010's | 6 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Grillot, K; Hager, JH; Heyman, R; Joseph, JD; Julien, J; Kahraman, M; Kaufman, J; Lai, A; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
| Diaugustine, RP; Hewitt, SC; Klotz, DM; Korach, KS | 1 |
| Galid, A; Kubista, E; Seifert, M | 1 |
| Neubauer, BL; Raghow, S; Steiner, MS | 1 |
| Bentrem, D; Dardes, RC; De Los Reyes, A; Jordan, VC; Lee, ES; O'Regan, RM; Schafer, JM | 1 |
| Bryant, HU; Burris, LL; Glasebrook, AL; Palkowitz, AD; Pearce, HL; Peer, C; Sporn, MB; Starling, JJ; Suh, N; Wang, Y; Williams, C | 1 |
| Bentrem, D; Dardes, RC; Jordan, VC; O'Regan, RM; Schafer, JM | 1 |
| Fabian, CJ; Kimler, BF | 1 |
| Gajdos, C; Jordan, VC | 1 |
| Chan, S | 1 |
| Cox, DA; Hurn, PD; Littleton-Kearney, MT; Ostrowski, NL; Rossberg, MI | 1 |
| Booser, DJ; Buzdar, A; Hudis, C; Jones, SE; Melemed, AS; Munster, PN; O'Shaughnessy, JA; Peterson, P; Pippen, JE; Winer, E | 1 |
| Licun, W; Tannock, IF | 1 |
| A'Hern, R; Detre, S; Dowsett, M; Johnston, SR; Riddler, S; Salter, J | 1 |
| Bartholomaeussen, M; Freddie, CT; Larsen, SS; Lykkesfeldt, AE | 1 |
| Christensen, GL; Freddie, CT; Lykkesfeldt, AE | 1 |
| Johansen, AM | 1 |
| Buzdar, AU; Deshmane, V; Krishnamurthy, S; Melemed, AS; Peterson, P | 1 |
| Lewiecki, EM | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Chines, AA; Komm, BS | 1 |
| Cuzick, J; Sestak, I | 1 |
| Calaf Alsina, J; Coronado MartÃn, PJ | 1 |
| Briarava, M; Mocellin, S; Nitti, D; Pilati, P | 1 |
10 review(s) available for ly 353381 and tamoxifen
| Article | Year |
|---|---|
Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
Topics: Aneuploidy; Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Clinical Trials, Phase II as Topic; Cyclooxygenase Inhibitors; Disease Progression; Eflornithine; Endpoint Determination; Enzyme Inhibitors; Estrogens; Female; Fenretinide; Gonadotropin-Releasing Hormone; Humans; Hyperplasia; Isoflavones; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Polyamines; Precancerous Conditions; Protein-Tyrosine Kinases; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Uterine Neoplasms | 2001 |
Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cinnamates; Drug Design; Forecasting; Humans; Molecular Biology; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Toremifene; Treatment Outcome | 2002 |
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2002 |
Selective estrogen receptor modulators: tissue actions and potential for CNS protection.
Topics: Animals; Breast Neoplasms; Cardiovascular System; Central Nervous System; Cognition; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Hormone Replacement Therapy; Humans; Hypothalamo-Hypophyseal System; Male; Neuroprotective Agents; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Neurotransmitter; Structure-Activity Relationship; Tamoxifen; Thiophenes; Uterus | 2002 |
Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
Topics: Breast Neoplasms; Female; Humans; Piperidines; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2005 |
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Vitamin D; Women's Health | 2009 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis.
Topics: Bone Density Conservation Agents; Breast; Endometrium; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2012 |
[Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Multicenter Studies as Topic; Organ Specificity; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Thromboembolism | 2013 |
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Norpregnenes; Piperidines; Postmenopause; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2016 |
2 trial(s) available for ly 353381 and tamoxifen
| Article | Year |
|---|---|
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Endometrium; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Patient Selection; Piperidines; Receptors, Estrogen; Survival Analysis; Tamoxifen; Thiophenes; Treatment Outcome | 2003 |
Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Piperidines; Postmenopause; Receptors, Steroid; Survival Analysis; Tamoxifen; Thiophenes; Time Factors; Treatment Failure | 2007 |
12 other study(ies) available for ly 353381 and tamoxifen
| Article | Year |
|---|---|
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Dogs; Drug Discovery; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Heterografts; Humans; Mice; Proteolysis; Rats; Selective Estrogen Receptor Modulators; Small Molecule Libraries; Tamoxifen | 2015 |
Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha.
Topics: Animals; Benzhydryl Compounds; Blotting, Northern; Estradiol Congeners; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Estrogens, Non-Steroidal; Female; Insulin-Like Growth Factor I; Mice; Mice, Knockout; Mitosis; Ovariectomy; Phenols; Piperidines; Precipitin Tests; Proliferating Cell Nuclear Antigen; Receptors, Estrogen; Ribonucleases; RNA, Messenger; Signal Transduction; Tamoxifen; Thiophenes; Uterus | 2000 |
The oestrogen receptor and its selective modulators in gynaecological oncology.
Topics: Antineoplastic Agents, Hormonal; Cinnamates; Estrogen Antagonists; Female; Genital Neoplasms, Female; Humans; Norpregnenes; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Thiophenes; Toremifene | 2000 |
Selective estrogen receptor modulators for the chemoprevention of prostate cancer.
Topics: Age Factors; Androgens; Anticarcinogenic Agents; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogens; Estrogens, Non-Steroidal; Humans; Isoflavones; Male; Phytoestrogens; Piperidines; Plant Preparations; Prostate; Prostatic Neoplasms; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2001 |
Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Humans; Mice; Mice, Nude; Piperidines; Pyrrolidines; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
Topics: Animals; Anticarcinogenic Agents; Binding, Competitive; Cell Division; Drug Interactions; Estradiol; Estradiol Congeners; Estrogen Antagonists; Ethinyl Estradiol; Female; Humans; Mammary Neoplasms, Experimental; Piperidines; Rats; Receptors, Estrogen; Tamoxifen; Thiophenes; Tumor Cells, Cultured; Uterus | 2001 |
Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice.
Topics: Animals; Cell Division; Down-Regulation; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Mice; Mice, Nude; Piperidines; Receptors, Estrogen; Tamoxifen; Thiophenes; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Methotrexate; Neoplasms, Hormone-Dependent; Piperidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Mice; Mice, Nude; Piperidines; Protein Biosynthesis; Proteins; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Trefoil Factor-1; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2003 |
The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Piperidines; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2004 |
A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.
Topics: Breast Neoplasms; Cathepsin D; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 1; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Progesterone; Repressor Proteins; RNA, Messenger; Tamoxifen; Thiophenes; Transcription Factors | 2004 |
Preventive therapy for breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Middle Aged; Piperidines; Preventive Medicine; Pyrrolidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2012 |